OGphoto/iStock via Getty Images
Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo regimen of Darzalex, the antibody therapy of Johnson & Johnson (NYSE:JNJ).
The marketing authorization is for Darzalex SC in combination with bortezomib, lenalidomide, and dexamethasone for multiple
